Regencell Bioscience surged 320.7% in morning trading. The shares soared 51507.7% this year.

Such explosive moves are rare, even in the volatile world of biotechnology. The market’s reaction signals a surge in investor interest and confidence, but it also raises questions about what is fueling this momentum.

Regencell's 51508% stock surge is entirely narrative-driven, with no revenue, clinical progress, or strategic developments to justify its valuation.

The company operates on anecdotal evidence and alternative medicine, lacking peer-reviewed data, clinical trials, or regulatory filings for its TCM-based ADHD/ASD treatments.

A razor-thin public float and insider lockups have fueled extreme volatility and speculative trading.